A Lexington company that aims to improve upon approved or nearly-approved drugs by making them more molecularly stable, Concert Pharmaceuticals is the fourth biotech in the past month to file plans to go public. The company said in a filing with the Securities and Exchange Commission dated Monday that it hopes to raise $75 million and be traded on the Nasdaq Global Market under the symbol, “CNCE.” The company did not specify the number of shares nor the price.
Help employers find you! Check out all the jobs and post your resume.
